ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1941

How Calculating Consensus Change Scores Can Go Wrong: Lessons from Multi-reader Imaging Assessments in Axial Spondyloarthritis

Ana Bento da Silva1, Sofia Ramiro2, Floris A. van Gaalen1, Robert Landewé3, Miranda van Lunteren1, Liese de Bruin1, Gizem Ayan4, Xenofon Baraliakos5, Monique Reijnierse6, Jürgen Braun7, Désirée Van Der Heijde1 and Manouk de Hooge8, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Bunde, Netherlands, 3Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, 4Ankara Research and Training Hospital, Ankara, Turkey, 5Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 6Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, 7Ruhr-University, Bochum, Germany; and Rheumatologische Versorgungszentrum (RVZ) Steglitz, Berlin, Germany, 8Department of Rheumatology, Ghent University Hospital, Ghent, Belgium

Meeting: ACR Convergence 2025

Keywords: Imaging, longitudinal studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1936–1971) Imaging of Rheumatic Diseases Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: In research, imaging findings are often assessed by multiple readers and individual readers’ scores are combined into aggregate scores to determine the presence of lesions. In longitudinal studies, the focus shifts to change in lesions. Diverse strategies for aggregating change scores are at hand, but may yield different results. We aimed to establish a methodological framework for aggregating change scores, using the example of syndesmophyte progression in axial spondyloarthritis (axSpA).

Methods: Data from the Sensitive Imaging in Ankylosing Spondylitis cohort were used, including patients with axSpA and established spinal damage. Syndesmophytes were assessed on vertebral corners (hereafter ‘level’) on conventional radiography (CR) and low-dose computed tomography (ldCT) of the spine at baseline and 2 years. CR were scored by 3 central readers and ldCT by 2, blinded for time order. Consensus was determined by majority reader agreement. New syndesmophytes (change score) were assessed by 2 strategies. Strategy 1 calculates change score per reader, then determines consensus on the change per level. Strategy 2 derives consensus change scores from consensus status scores (syndesmophyte present/absent) (Box 1). The means and standard deviations (SD) of the different aggregate change scores were compared. For analyses at the patient level, the total number of new syndesmophytes was averaged across readers, only if patients had ≤25% scores missing per spinal segment at both timepoints.

Results: Complete data from 52 patients were used. In example 3 (Figure 1a), the two strategies yielded different results. When consensus change scores are derived from change scores of individual readers (strategy 1), because only reader C detected a new syndesmophyte, there is no new syndesmophyte in the aggregated score. In contrast, when consensus status scores are determined first (strategy 2), indicating no syndesmophyte at baseline but one at 2 years, the consensus change score suggests a new syndesmophyte.Strategy 2 is more sensitive, identifying 1.2 times more new syndesmophytes on CR (mean [SD]: 0.86 [1.00] vs 0.69 [0.95]) and 3.1 times more on ldCT (7.23 [7.46] vs 2.35 [4.44]). However, this is accompanied with higher variability (Figure 1b). Only strategy 1 represents “true consensus” among readers, but requires site-level agreement, which compromises sensitivity to change at the patient level. At the patient level, the total number of new syndesmophytes should be calculated as the average of the total number across all readers (CR: 0.66 [1.10]; ldCT: 5.55 [6.65]).

Conclusion: Consensus change scores should be derived from individual readers’ change scores. Strategy 1 approaches true change best, while strategy 2 artificially inflates change. At the patient level, the average total number of new syndesmophytes across readers should be reported. While we focus on syndesmophyte progression in axSpA, this framework is broadly applicable to imaging findings across multiple diseases. Advanced statistical analyses beyond descriptive purposes should preferably be performed on individual readers’ scores, using multilevel models that properly account for variability in reader assessment.

Supporting image 1Box 1. Explanation of two strategies for defining a consensus change score in multi-reader imaging assessments

Supporting image 2Figure 1. Comparison of strategies for assessing new syndesmophytes in patients with axial spondyloarthritis after 2 years, illustrating a broad imaging framework for consensus change scores


Disclosures: A. Bento da Silva: None; S. Ramiro: AbbVie, 2, 5, Eli Lilly, 2, 5, Galapagos/Alfasigma, 2, 5, Janssen, 2, MSD, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi, 2, 5, UCB, 2, 5; F. van Gaalen: AbbVie, 2, BMS, 2, Eli Lilly, 2, Jacobus Stichting, 5, MSD, 2, Novartis, 2, 5, Stichting ASAS, 5, Stichting vrienden van Sole Mio, 5, UCB, 5; R. Landewé: AbbVie/Abbott, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, Janssen, 2, Joint Imaging BV, 12, Director, Novartis, 2, Pfizer, 2, Rheumatology Consultancy BV, 12, Director, UCB, 2; M. van Lunteren: None; L. de Bruin: None; G. Ayan: None; X. Baraliakos: AbbVie, 2, 5, 6, 12, Paid Instructor, Advanz, 2, 6, 12, Paid instructor, Alexion, 2, 6, 12, Paid instructor, Alphasigma, 2, 6, 12, Paid instructor, Amgen, 2, 6, 12, Paid instructor, BMS, 2, 6, 12, Paid instructor, Celgene, 6, Celltrion, 2, 5, 6, 12, Paid instructor, Cesas, 2, 6, 12, Paid instructor, Chugai, 2, 6, Clarivate, 6, 12, Paid instructor, Galapagos, 2, 6, 12, Paid instructor, J&J, 2, 6, 12, Paid instructor, Janssen, 5, Lilly, 2, 6, 12, Paid instructor, Merck, 6, MoonLake, 2, 5, 6, 12, Paid instructor, MSD, 2, Novartis, 2, 5, 6, 12, Paid instructor, Peervoice, 2, 6, 12, Paid instructor, Pfizer, 2, 6, 12, Paid instructor, Roche, 2, 6, 12, Paid instructor, Sandoz, 2, 6, 12, Paid instructor, Springer, 2, 6, 12, Paid instructor, Stada, 2, 6, 12, Paid instructor, Takeda, 2, 6, 12, Paid instructor, UCB, 2, 6, 12, Paid instructor, Zuellig, 2, 6, 12, Paid instructor; M. Reijnierse: None; J. Braun: None; D. Van Der Heijde: AbbVie, 2, Alfasigma, 2, Annals of the Rheumatic Diseases, 12, Associate editor, ArgenX, 2, Bristol Myers Squibb, 2, Eli Lilly and Company, 2, Grey-Wolf Therapeutics, 2, Imaging Rheumatology BV, 12, Director, Janssen, 2, Journal of Rheumatology, 12, Editorial board member, Novartis, 2, Pfizer, 2, RMD Open, 12, Editoral board member, Takeda, 2, UCB, 2; M. de Hooge: UCB pharma, 2.

To cite this abstract in AMA style:

Bento da Silva A, Ramiro S, van Gaalen F, Landewé R, van Lunteren M, de Bruin L, Ayan G, Baraliakos X, Reijnierse M, Braun J, Van Der Heijde D, de Hooge M. How Calculating Consensus Change Scores Can Go Wrong: Lessons from Multi-reader Imaging Assessments in Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/how-calculating-consensus-change-scores-can-go-wrong-lessons-from-multi-reader-imaging-assessments-in-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-calculating-consensus-change-scores-can-go-wrong-lessons-from-multi-reader-imaging-assessments-in-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology